Form 4: Lisata Therapeutics Director Klosk Receives Equity Grant

Lisata Therapeutics Director Steven M. Klosk was granted 30,456 restricted stock units, increasing his beneficial ownership.

Summary

• Steven M. Klosk, a Director of Lisata Therapeutics, Inc. (LSTA), was granted 30,456 restricted stock units (RSUs).
• The transaction occurred on January 9, 2026.
• These RSUs were granted under the Issuer's 2018 Equity Incentive Compensation Plan.
• The RSUs will vest on January 9, 2027.
• Following this transaction, Mr. Klosk beneficially owns 95,815 shares of common stock, which includes the 30,456 unvested RSUs.
• The reported price for the acquisition was $0.

Sentiment

Score: 6

Explanation: The grant of restricted stock units to a director is a standard compensation practice that aligns management's interests with shareholders. While not a direct cash investment, it indicates continued involvement and potential confidence in the company's future performance.

Positives

• A director receiving an equity grant aligns their interests with shareholders, potentially indicating confidence in the company's future.
• The grant is part of an established equity incentive plan, suggesting standard compensation practices.

Negatives

• The shares are restricted stock units and not an open market purchase, meaning they are compensation rather than a direct investment of personal capital.
• The RSUs are unvested, meaning the director does not fully own them until January 9, 2027.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Potentially positive, as the director's increased equity stake aligns their interests with shareholder value creation.
• Employees: No direct impact mentioned in this filing.

Next Steps

• The 30,456 restricted stock units granted to Steven M. Klosk are scheduled to vest on January 9, 2027.

Key Dates

Recommendation

This Form 4 filing reports a routine equity grant to a director as part of their compensation. While it aligns the director's interests with shareholders, it does not provide new fundamental information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Investors should consider this information in the broader context of the company's overall financial reports and market position.

Keywords

Lisata Therapeutics, LSTA, Steven M. Klosk, Form 4, SEC filing, insider transaction, restricted stock units, RSU, equity grant, director compensation